BHCM
HRMY icon

Boulder Hill Capital Management’s Harmony Biosciences HRMY Stock Holding History

Boulder Hill Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8,500
Closed -$376K – 180
2022
Q3 		$376K Buy
+8,500
New +$415K 0.29% 89

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Boulder Hill Capital Management's HRMY Position: Q4 2022 in Review

Boulder Hill Capital Management sold out of Harmony Biosciences (HRMY) in Q4 2022, closing a stake of 8,500 shares — an estimated $376K sold.

Boulder Hill Capital Management first reported a position in HRMY in Q3 2022 and held it in 1 quarter. The position peaked at $376K in Q3 2022. 242 funds tracked by Wall St. Rank hold HRMY as of Q4 2022.

  • Boulder Hill Capital Management reported no remaining Harmony Biosciences position as of Q4 2022 after selling out during the quarter.
  • Boulder Hill Capital Management sold 8,500 Harmony Biosciences shares in Q4 2022, an estimated $376K.
  • Boulder Hill Capital Management first reported a position in Harmony Biosciences in Q3 2022 and held it in 1 quarter.
  • Boulder Hill Capital Management's Harmony Biosciences position peaked at $376K in Q3 2022.
  • 242 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2022.

Based on Boulder Hill Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.